|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ABII 10-K filed Mar 12, 2010. Reacquisition costs In November 2008, we entered into an agreement under which we would, subject to the terms and conditions of the agreement, reacquire exclusive rights to market Abraxane® in the United States. In accordance with this agreement, the Co-Promotion Agreement ended effective January 2009 and we agreed to pay AstraZeneca a $268.0 million fee by March 31, 2009. For the year ended December 31, 2008, we recorded a charge of $158.9 million representing the net amount of previously deferred revenue associated with the Co-Promotion Agreement included in our balance sheet and the $268.0 million termination payment. These excerpts taken from the ABII 10-K filed Mar 6, 2009. Reacquisition costs In November 2008, we entered into an agreement under which we would, subject to the terms and conditions of the agreement, reacquire exclusive rights to market Abraxane® in the United States. In accordance with this agreement, the Co-Promotion Agreement ended effective January 2009 and we agreed to pay AstraZeneca a $268.0 million fee by March 31, 2009. For the year ended December 31, 2008, we recorded a charge of $158.9 million representing the net amount of previously deferred revenue associated with the Co-Promotion Agreement included in our balance sheet and the $268.0 million termination payment. Reacquisition costs conditions of the agreement, reacquire exclusive rights to market Abraxane® in the United States. In accordance with this agreement, the Co-Promotion Agreement ended effective January 2009 and we agreed to pay AstraZeneca a $268.0 million fee by March 31, 2009. For the year ended December 31, 2008, we recorded a charge of $158.9 million representing the net amount of previously deferred revenue associated with the Co-Promotion Agreement included in our balance sheet and the $268.0 million termination payment. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for ABII: |
| |||||||
